Topical & Oral · Hair Loss · Established Treatment

Minoxidil

How this page was made

This page was written with AI assistance and reviewed against the sources listed under References below. It is general information only, not medical advice. See our full disclaimer for how SHEA creates and reviews treatment information.

What it is

Minoxidil is a vasodilator originally developed as a blood pressure medication; hair growth was an observed side effect that led to its development as a topical hair loss treatment. Its exact mechanism for hair growth isn't fully understood, but it's believed to prolong the growth (anagen) phase of the hair cycle and improve blood flow to follicles.

Topical minoxidil (2% and 5% solutions or foams) is FDA-approved in the United States for androgenetic alopecia. Oral minoxidil, at low doses, has become increasingly used for hair loss in recent years, but this is an off-label use in most places — minoxidil is orally approved as a blood pressure medication at much higher doses, not specifically for hair loss, and its regulatory status for this off-label use can vary by country.

Some Korean clinics deliver minoxidil by scalp injection (mesotherapy) rather than topical application. This is a different, less-studied route of administration, and injecting minoxidil into the scalp should not be treated as equivalent to its established topical or oral routes. See the Mesotherapy for Hair page for more on this specific consideration.

Why people consider it

Androgenetic (pattern) hair loss, where it is one of the most established medical treatments
They want a topical option rather than an oral medication
They're considering low-dose oral minoxidil, often after topical use hasn't been tolerated well or has been inconvenient
They're considering combining it with another treatment such as PRP

What the experience is like

Topical minoxidil is applied to the scalp, typically once or twice daily depending on the formulation and concentration. Oral minoxidil, when prescribed off-label for hair loss, is generally used at much lower doses than those historically used to treat severe hypertension.

Results take time. Clinical studies generally assess changes over several months rather than weeks, and continued use is usually required to maintain any benefit. Stopping minoxidil generally leads to gradual loss of hair that was maintained or gained because of treatment.

A 2024 randomized trial comparing oral minoxidil 5 mg daily with topical 5% minoxidil twice daily in men found broadly similar overall results after 24 weeks. Oral minoxidil did not demonstrate overall superiority to topical treatment.

Limitations & considerations

Oral minoxidil has real, dose-related side effects

In the largest safety study of low-dose oral minoxidil for hair loss, involving 1,404 patients, hypertrichosis (unwanted hair growth on the face or body) was the most common adverse effect at 15.1%, followed by lightheadedness at 1.7%, fluid retention at 1.3%, and tachycardia at 0.9%. Treatment was discontinued because of adverse effects in fewer than 2% of patients. At the much higher doses used to treat severe hypertension, oral minoxidil carries a labeled warning for pericardial effusion, occasionally progressing to cardiac tamponade, reported in about 3% of treated patients not receiving dialysis. That figure comes from antihypertensive use and should not be interpreted as the expected risk with typical low-dose hair-loss treatment.

Topical minoxidil can cause scalp irritation, itching, or unwanted facial hair growth from product transfer; oral minoxidil has a different and more systemic side-effect profile
Oral minoxidil can cause unwanted facial or body hair growth as well as systemic effects such as lightheadedness, fluid retention, increased heart rate, headache, or swelling
Because oral minoxidil is a systemic vasodilator, medical history, cardiovascular conditions, kidney function, blood pressure, and other medications can matter when deciding whether it is appropriate
Higher oral doses may increase both hair-growth effects and adverse effects; a higher dose should not automatically be interpreted as better treatment
Minoxidil does not permanently correct the underlying process causing androgenetic alopecia. Continued treatment is generally needed to maintain its effect
Oral minoxidil has not been shown to be clearly superior to topical minoxidil. In a 2024 randomized comparison in men, oral 5 mg daily did not demonstrate overall superiority to topical 5% minoxidil after 24 weeks
Injectable minoxidil used in scalp mesotherapy is a separate route with a different and less established evidence base
No specific amount of hair growth or other outcome can be guaranteed

Evidence note

Topical minoxidil has a substantial clinical evidence base for androgenetic alopecia. In a 48-week randomized, double-blind, placebo-controlled trial involving 393 men, 5% topical minoxidil produced greater increases in nonvellus hair count than 2% minoxidil or placebo. The 5% formulation also caused more itching and local irritation than the 2% formulation.

Evidence for low-dose oral minoxidil has grown considerably but is newer. A 2022 systematic review with meta-regression found a positive dose-dependent association between oral minoxidil dose and changes in hair density and diameter. The analysis also found dose-dependent associations with adverse effects including hypertrichosis and cardiovascular symptoms. Meta-regression can identify associations across studies but does not establish the ideal dose for an individual patient.

A large 2021 retrospective multicenter study included 1,404 patients receiving low-dose oral minoxidil for at least three months. Hypertrichosis occurred in 15.1%. Reported systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%), and insomnia (0.2%). No life-threatening adverse effects were observed in this cohort, and treatment was discontinued because of adverse effects in fewer than 2% of patients. The study was retrospective and had no untreated control group.

Direct comparative evidence is also available. A 2024 double-blind randomized trial enrolled 90 men with androgenetic alopecia to oral minoxidil 5 mg daily or topical minoxidil 5% twice daily for 24 weeks. Sixty-eight participants completed the study. Most efficacy measures showed no statistically significant difference between the groups, although terminal hair density at the vertex favored oral treatment. The authors concluded that oral minoxidil did not demonstrate overall superiority to topical minoxidil.

Minoxidil is also studied in combination with other treatments, but evidence for a combination should be evaluated separately from evidence for minoxidil itself. A 2024 systematic review of PRP plus topical minoxidil found possible additional benefit over minoxidil alone, but the certainty of evidence was rated low to very low. See the PRP for Hair page for that evidence.

References

Peer-reviewed literature and prescribing information.

1. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology, 2002;47(3):377–385.

Peer-reviewed · Randomized double-blind placebo-controlled trial · n=393 men · 48 weeks

2. Gupta AK, Hall DC, Talukder M, Bamimore MA. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disorders, 2022;8(5):355–361.

Peer-reviewed · Systematic review with meta-regression

3. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of Dermatology, 2021;84(6):1644–1651.

Peer-reviewed · Retrospective multicenter safety study · n=1,404

4. Penha MA, Miot HA, Kasprzak M, Ramos PM. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatology, 2024;160(6):600–605.

Peer-reviewed · Double-blind randomized comparative trial · n=90 enrolled · 68 completed

5. Yao J, Zhu L, Pan M, Shen L, Tang Y, Fan L. The additive value of platelet-rich plasma to topical Minoxidil in the treatment of androgenetic alopecia: A systematic review and meta-analysis. PLOS ONE, 2024;19(8):e0308986.

Peer-reviewed · Systematic review and meta-analysis · 5 RCTs · Low to very low certainty

6. Minoxidil tablets prescribing information. Oral minoxidil carries a boxed warning concerning serious cardiovascular effects, including pericardial effusion that may progress to cardiac tamponade.

Regulatory prescribing information · Oral minoxidil